GKB Ophthalmics Ltd. conducted its annual independent directors meeting on March 18, 2026, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013. The meeting represents a key governance milestone for the pharmaceutical company for the year 2025-26.

Meeting Attendance and Composition

The independent directors meeting saw full attendance from all three independent board members:

Key Agenda Items and Assessments

The independent directors conducted comprehensive evaluations across multiple governance areas during their session. The meeting agenda focused on three primary assessment areas as mandated by regulatory frameworks.

The directors reviewed the performance of non-independent directors and evaluated the board's overall effectiveness. Additionally, they assessed the performance of the company's chairperson, incorporating feedback from both executive and non-executive directors to ensure a balanced evaluation process.

Information Flow Assessment

A critical component of the meeting involved evaluating the quality, quantity, and timeliness of information flow between GKB Ophthalmics' management and the board. This assessment ensures that directors receive adequate and timely information necessary for effective decision-making and oversight responsibilities.

Meeting Duration and Compliance

The meeting was formally communicated to BSE Limited through the company secretary, Pooja Bicholkar, ensuring transparency and compliance with listing obligations. This independent directors meeting forms part of GKB Ophthalmics' ongoing commitment to maintaining robust corporate governance standards in the pharmaceutical sector.

GKB Ophthalmics Limited has reported a remarkable turnaround in its Q3FY26 financial performance, posting a standalone profit of ₹98.08 lakhs for the quarter ended December 31, 2025, compared to a loss of ₹16.74 lakhs in the corresponding quarter of the previous year. The company's Board of Directors approved these unaudited financial results during their meeting held on February 12, 2026.

Standalone Financial Performance

The company's standalone operations showed mixed results with revenue declining but profitability improving significantly. Despite the revenue challenges, the company managed to control expenses effectively, leading to the positive bottom-line performance.

The improvement in profitability was supported by higher other income of ₹354.12 lakhs compared to ₹181.43 lakhs in Q3FY25. Total expenses decreased to ₹699.16 lakhs from ₹941.84 lakhs, reflecting better cost management across various expense categories.

Consolidated Results Show Strong Growth

The consolidated financial results presented an even more impressive picture, with the company reporting a profit of ₹70.72 lakhs in Q3FY26 against a loss of ₹190.53 lakhs in the same quarter last year.

The substantial increase in consolidated revenue was primarily driven by higher purchases of stock-in-trade, which rose to ₹3,943.26 lakhs from ₹1,507.07 lakhs, indicating expanded trading activities across the group's operations.

Nine-Month Performance and Subsidiary Liquidation

For the nine months ended December 31, 2025, the standalone operations reported a loss of ₹168.48 lakhs compared to ₹362.84 lakhs in the corresponding period of FY25, showing significant improvement. The consolidated nine-month results showed a profit of ₹190.77 lakhs versus a loss of ₹295.04 lakhs in the previous year.

A significant development during the period was the voluntary liquidation of GSV Ophthalmics Private Limited, the company's material subsidiary. The company received ₹7.95 crores against its total investment of ₹11.70 crores by December 31, 2025. Subsequently, the remaining balance of ₹3.75 crores and a net dividend of ₹62.74 lakhs were received in January and early February 2026.

Legal and Regulatory Updates

The company disclosed that it faces a recovery order of ₹8.82 crores from the Labour Commissioner, Industrial Tribunal cum Labour Court, Panaji, Goa. GKB Ophthalmics is challenging this order and plans to file a writ petition before the High Court seeking appropriate relief once the recovery certificate is issued.

Additionally, the company recognized an incremental employee benefit expense of ₹29.59 lakhs during Q3FY26 due to the implementation of new Labour Codes notified by the Government of India on November 21, 2025, specifically related to past service cost for gratuity liability.

Regulatory Compliance and Publication

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GKB Ophthalmics published the extract of its unaudited standalone and consolidated financial results in newspapers. The financial results extract was published in Free Press Journal (Mumbai Edition) and Pudhari (Marathi) on February 14, 2026.

The company submitted the newspaper cuttings to BSE Limited on February 14, 2026, with scrip code 533212, fulfilling its disclosure obligations to the stock exchange.

Business Operations and Outlook

GKB Ophthalmics operates primarily in manufacturing and trading of unfinished ophthalmic lenses made of plastic. The company's operations are reviewed as a single operating segment by the Chief Operating Decision Maker. The paid-up equity share capital remained stable at ₹504.06 lakhs with a face value of ₹10 per share throughout the reporting periods.